A smartphone application providing diet and physical activity information for the prevention of gestational diabetes

ISRCTN ISRCTN59044843
DOI https://doi.org/10.1186/ISRCTN59044843
Secondary identifying numbers TCTR20210317002
Submission date
05/04/2021
Registration date
12/04/2021
Last edited
14/02/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
The study aims to evaluate a specific behavioral intervention for the prevention of the development of gestational diabetes during 24-28 weeks of gestation among pregnant women whose initial screening before 20 weeks of gestation does not show gestational diabetes.

Who can participate?
Pregnant women aged 18-50 years who previously received gestational diabetes screening before 20 weeks of gestation according to institutional guidelines with normal results.

What does the study involve?
Participants will either receive standard antenatal care or individual counseling on diet and physical activity and weekly information on behavioral modification will be provided via the LINE smartphone application. Participants will be followed to determine the development of gestational diabetes at 24-28 weeks of gestation as well as other pregnancy outcomes.

What are the possible benefits and risks of participating?
Participants would benefit by reducing the risk of gestational diabetes along with developing healthier behavior during pregnancy.

Where is the study run from?
Faculty of Medicine Siriraj Hospital (Thailand)

When is the study starting and how long is it expected to run for?
From July 2020 to February 2023

Who is funding the study?
Thailand Research Fund (Thailand) and the Medical Research Council (UK)

Who is the main contact?
Dr Dittakarn Boriboonhirunsarn, dittakarn.bor@mahidol.ac.th

Contact information

Dr Dittakarn Boriboonhirunsarn
Scientific

2 Wanglang Road
Siriraj
Bangkoknoi
Bangkok
10700
Thailand

ORCiD logoORCID ID 0000-0002-5901-5923
Phone +66 818085718
Email dittakarn.bor@mahidol.ac.th

Study information

Study designInterventional randomized controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet.
Scientific titleBehavioral intervention for prevention of gestational diabetes
Study objectivesBehavioral intervention can prevent development of GDM during 24-28 weeks of gestation in women with normal initial GDM screening before 20 weeks of gestation.
Ethics approval(s)Approved 22/11/2019, Siriraj Institutional Review Board (SIRB) (Human Research Protection Unit, Faculty of Medicine Siriraj Hospital, Mahidol University, His Majesty the King's 80th Birthday Anniversary 5th December 2007 Building, 2nd floor, Room 210, 2 Wang Lang Road Bangkoknoi, Bangkok 10700, Thailand; +662419 2667 - 72; siethics@mahidol.ac.th), ref: Si 796/2019
Health condition(s) or problem(s) studiedGestational diabetes during 24-28 weeks of gestation in women with normal initial GDM screening
InterventionThe intervention group receives individual counseling on nutrition and physical activity together with weekly information about behavioral modification via smartphone (LINE application) until gestational diabetes mellitus (GDM) screening at 24-28 weeks of gestation. The control group receives standard antenatal care.
Intervention typeBehavioural
Primary outcome measureDevelopment of gestational diabetes mellitus (GDM) during 24-28 weeks of gestation measured using GDM screening at 24-28 weeks
Secondary outcome measuresPregnancy outcomes related to gestational diabetes mellitus (GDM), such as preterm delivery, Large for Gestational Age (LGA), macrosomia, or cesarean section measured from participant notes at delivery
Overall study start date01/06/2019
Completion date28/02/2023

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexFemale
Target number of participants820
Total final enrolment820
Key inclusion criteria1. Aged between 18 and 50 years
2. Gestational age <20 weeks
3. Received gestational diabetes mellitus (GDM) screening according to institutional guideline
4. Have a smartphone with the LINE application
Key exclusion criteria1. Pre-pregnancy diabetes
2. Intrauterine fetal death or major anomalies or any conditions that pregnancy termination is indicated
3. Do not agree to participate
Date of first enrolment31/07/2020
Date of final enrolment31/12/2021

Locations

Countries of recruitment

  • Thailand

Study participating centre

Faculty of Medicine Siriraj Hospital
2 Wanglang Road
Siriraj
Bangkoknoi
Bangkok
10700
Thailand

Sponsor information

Thailand Research Fund
Government

14th Floor SM Tower
979/17-21 Phaholyothin Road
Samsan Nai
Phyathai
Bangkok
10400
Thailand

Phone +66 2278 8200
Email callcenter@trf.or.th
Website http://www.trf.or.th/eng/

Funders

Funder type

Government

Thailand Research Fund
Government organisation / Local government
Alternative name(s)
TRF
Location
Thailand
Medical Research Council
Government organisation / National government
Alternative name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC
Location
United Kingdom

Results and Publications

Intention to publish date31/12/2023
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryOther
Publication and dissemination planPlanned publication in a high-impact peer-review journals.
IPD sharing planThe datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

Editorial Notes

14/02/2023: The following changes were made to the trial record:
1. The overall trial end date was changed from 30/06/2022 to 28/02/2023.
2. The intention to publish date was changed from 31/12/2022 to 31/12/2023.
08/04/2021: Trial’s existence confirmed by Siriraj Institutional Review Board.